¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"immunologic high dose tolerance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic technique
    ¸é¿ªÇÐÀû±â¼ú
  • acquired tolerance
    ȹµæ³»¼º
  • adoptive tolerance
    ÀÔ¾ç¸é¿ªÇã¿ë
  • cross-tolerance
    ±³Â÷³»¼º
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
  • glucose tolerance test
    ´çºÎÇϰ˻ç
  • low-zone tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´ç³»¼º°Ë»ç
  • oxygen tolerance
    »ê¼Ò³»¼º
  • self-tolerance
    1. ÀÚ°¡°ü¿ë 2. ÀÚ°¡³»¼º
  • high altitude
    °íÁö-, °í¼Ò-
  • high altitude illness
    °í¼Òº´
  • high altitude polycythemia
    ³ôÀº°÷ÀûÇ÷±¸Áõ°¡Áõ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximum dose
    ÃÖ´ë¿ë·®, ÃÖ´ë¼±·®
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
  • radiation dose
    ¹æ»ç¼±·®
  • radiation absorbed dose
    Èí¼ö¼±·®
  • skin dose
    ÇǺμ±·®
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic reaction
    (¢¡immune) ¸é¿ª¹ÝÀÀ
  • immunologic technique
    ¸é¿ªÇÐÀû±â¼ú
  • immunologic deficiency state
    ¸é¿ª°áÇÌ»óÅÂ
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªºÒÀÀ»óÅÂ
  • acceleration tolerance
    °¡¼Ó³»¼º
  • acquired tolerance
    ȹµæÇã¿ë, ÈÄõ³»¼º, ÈÄõÇã¿ë, ȹµæ°ü¿ë
  • adoptive tolerance
    ÀÔ¾ç¸é¿ªÇã¿ë
  • cross-tolerance
    ±³Â÷³»¼º
  • carbohydrate tolerance test
    ź¼öÈ­¹°³»¼º½ÃÇè
  • cortisone glucose tolerance test
    ÄÚ¸£Æ¼¼ÕÆ÷µµ´çºÎÇϽÃÇè
  • cross tolerance
    ±³Â÷³»¼º
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
  • glucose insulin tolerance test
    Æ÷µµ´çÀν¶¸°°ßµõ°Ë»ç
  • glucose tolerance test
    Æ÷µµ´ç°ßµõ°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • immunologic intervention
    ¸é¿ª(ÇÐÀû)Á¶Á¤.
  • immunologic memory
    ¸é¿ª±â¾ï.
  • immunologic reaction
    ¸é¿ª¹ÝÀÀ
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunologic surveillance
    ¸é¿ª°¨½Ã(±â±¸).
  • immunologic system
    ¸é¿ª°è.
  • immunologic technique
    ¸é¿ªÇÐÀû±â¼ú
  • immunologic test
    ¸é¿ª°Ë»ç
  • immunologic thrombocytopenic purpura
    ¸é¿ª¼º Ç÷¼ÒÆÇ°¨¼Ò¼º ÀÚ¹Ý
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªÇÐÀû ºÒÀÀ»óÅÂ(ÝÕëëßÒ÷¾)
  • GTT= glucose tolerance test
    ´çºÎÇÏ °Ë»ç.
  • Glucose tolerance
    ³»´ç·Â(Ò±ÓØÕô)
  • Gudmand-Hoyer lactose tolerance test
    ±¸µÎ¸¸-È£À̾î À¯´çºÎÇϽÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high dose rate intraluminal radiotherapy
    °í¼±·®À² °ü³»¹æ»ç¼±Ä¡·á
  • cumulative dose ; cumulate dose
    ´©Àû¿ë·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® , [¿¹¹æ] ÁýÀû¼±·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® .[¿¹¹æ]ÁýÀû¼±·®.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • congenital immunologic thrombocytopenia
    ¼±Ãµ¼º ¸é¿ª¼º Ç÷¼ÒÆÇ°¨¼ÒÁõ(¡­Øóæ¹ àõúìá³÷ùÊõá´ñø).
  • immunologic
    ¸é¿ªÀÇ
  • immunologic deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • immunologic deficiency syndrome
    ¸é¿ª°áÇÌ ÁõÈıº(¡­ÌÀù¹ ñøý¦ÏØ)
  • immunologic electron microscopy
    ¸é¿ªÀüÀÚÇö¹Ì°æ¹ý.
  • immunologic engineering
    ¸é¿ª°øÇÐ.
  • immunologic function
    ¸é¿ª±â´É.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-density lipoprotein
    °í¹Ðµµ ÁöÁú´Ü¹éÁú(ÍÔÚËÓøò·òõÓ±ÛÜòõ)
  • high-energy bond
    °í(ÍÔ)¿¡³ÊÁö °áÇÕ(Ì¿ùê)
  • high-energy compound
    °í(ÍÔ)¿¡³ÊÁö È­ÇÕ¹°(ûùùêÚª)
  • high-energy ion scattering
    °í(ÍÔ)¿¡³ÊÁö À̿»ê¶õ(ߤկ)
  • high-energy phosphate donor
    °í(ÍÔ)¿¡³ÊÁö ÀÎ»ê°ø¿©ÀÚ(×òß«Íêæ¨í­)
  • high-level promoter
    °íÀ§(ÍÔêÈ)ÇÁ·Î¸ðÅÍ
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • high-mannose glycoproteins
    ´Ù(Òý)¸¸³ë½º ´ç´Ü¹éÁú(ÓØÓ±ÛÜòõ)
  • high-mannose oligosaccharides
    ´Ù(Òý)¸¸³ë½º °ú´çÁú(ÍûÓØòõ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • high-performance liquid chromatography
    °í¼º´É(ÍÔàõÒö) ¾×ü(äûô÷) Å©·Î¸¶Åä±×·¡ÇÇ
  • high-potential iron protein
    °íÀüÀ§(ÍÔï³êÈ) ö´Ü¹éÁú(ôÑÓ±ÛÜòõ)
  • high-pressure liquid chromatography
    °í¾Ð(ÍÔäâ) ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • high-quality proteins
    °í±Þ ´Ü¹éÁú(ÍÔÐäÓ±ÛÜòõ)
  • high-speed sedimentation equilibrium
    "°í¼Ó ħ°­ÆòÇü(ÍÔáÜöØË½øÁû¬)(¹ý,Ûö)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
  • relative dose
    ºñ±³Á¶»ç·®, »ó´ëÁ¶»ç·®
  • single dose
    ÀÏȸ·®
  • skin dose
    ÇǺμ±·®
  • high cellular component
    °í¼¼Æ÷±¸¼º¼ººÐ
  • high echo area
    °í¿¡ÄÚ ±¸¿ª
  • high energy
    °í¿¡³ÊÁö
  • high energy radiation
    °íÀü¾ÐÁ¶»ç
  • high field MR scanner
    °íÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
  • high frequency
    °íºóµµ, °íÁÖÆÄ
  • high intensity proton flow
    °í°­µµ¾çÀÚÀ¯µ¿
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AITT arginine insulin tolerance test; augmented insulin tolerance test
ATT arginine tolerance test; aspirin tolerance time
ETT endotracheal tube; epinephrine tolerance test; exercise tolerance test; exercise treadmill test; ext...
LTT lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te...
ICU infant care unit; immunologic contact urticaria; intensive care unit; intermediate care unit
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HDMP High dose methyl prednisolone
HDT High dose therapy
HD High-dose
HDara-C High-dose ara-C
HDT High-dose chemotherapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carbohydrate tolerance
    ź¼öÈ­¹° ºÎÇÏ, ź¼öÈ­¹° ³»Àμº
  • cortisone glucose tolerance test
    ÄÚ¸£Æ¼¼Õ Æ÷µµ´ç ºÎÇÏ ½ÃÇè
  • cross tolerance
    ±³Â÷ ³»¼º
  • drug disposition tolerance
    ¾à¹° ºÐÇØ ³»¼º
  • EDTA tolerance test
    EDTA ³»¼º °Ë»ç
    Á¤¸Æ Åõ¿©ÇÏ¿© ºÎ°©»ó¼± È£¸£¸óÀÇ ºÐºñ¸¦ ÃËÁø½ÃŰ´Â °ÍÀÌ ¸ñÀûÀÌ´Ù.
  • exercise tolerance test
    ¿îµ¿ ºÎÇÏ °Ë»ç
  • immunological tolerance
    ¸é¿ª ³»¼º
    ´Ù¸¥ »óÅ¿¡¼­´Â ü¾×¼º ¶Ç´Â ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» À¯¹ßÇÒ ¼ö Àִ ƯÁ¤ÀÇ Ç׿ø¿¡ ´ëÇØ¼­, ¸²ÇÁ°è Á¶Á÷ÀÇ Æ¯ÀÌÀû ¹«¹ÝÀÀ¼ºÀÌ ÀϾµµ·Ï µÇ´Â °ÍÀ» Ư¡ÀûÀ¸·Î ÇÏ´Â ¸é¿ª ¹ÝÀÀ.
  • individual tolerance
    °³Àκ° ³»¼º
    ºñÁ¤»óÀûÀ¸·Î ´ë·®ÀÇ ¾à¹°¿¡ ´ëÇÏ¿© µ¶¿µÇâÀ» ¹ÞÁö ¾Ê°í °ßµð¸ç ¶ÇÇÑ ÀÏÁ¤·®ÀÇ ¾à¹°ÀÇ Áö¼ÓÀûÀÎ »ç¿ë¿¡ ´ëÇØ¼­ È¿°úÀÇ °¨¼Ò¸¦ ³ªÅ¸³»´Â ´É·Â.
  • lactose tolerance test
    ¶ôÅä¿À½º ³»¼º ½ÃÇè
  • median tolerance limit
    ¹Ý¼ö »ýÁ¸ ÇÑ°è ³óµµ
  • pain tolerance
    µ¿Åë ³»¼º, ÅëÁõ ³»¼º
    ÂüÀ» ¼ö ÀÖ´Â ÅëÁõÀÇ °¡Àå Å« ¼öÁØ.
  • pharmacodynamic tolerance
    ¾à¿ªÇÐÀû ³»¼º
  • poison tolerance
    µ¶¹° ³»¼º
    Áö¼ÓÀûÀÎ µ¶¼º ¹°Áú¿¡ ÀÇÇØ »ýü°¡ ±× µ¶¼º ¹°Áú¿¡ ÀúÇ×¼ºÀ» ³ªÅ¸³»´Â °Í.
  • tolerance
    ³»¾à¼º, ³»¼º, ³»¿ë·Â, Çã¿ë, °ü¿ë
    1. º¸Åë ¾à¹°À̳ª µ¶¹°ÀÇ ¸¹Àº »ç¿ë·®À» °ßµð¾î ³¾ ¼ö ÀÖ´Â ´É·Â. 2. ÈÄõÀûÀ¸·Î ȹµæµÈ ¾à¹° ³»¼º. ¹Ýº¹ÀûÀÎ µ¿·®ÀÇ »ç¿ë·®¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀÇ °¨¼Ò ȤÀº °°Àº ¹ÝÀÀÀ» ¾ò±â À§Çؼ­ Áõ°¡µÈ »ç¿ë·®À» ¿ä±¸ÇÏ´Â °Í.
  • tolerance span
    Àγ» ±â°£
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
immunologic capping The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens.
(12 Dec 1998)
immunologic deficiency syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
(12 Dec 1998)
immunologic diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated or both.
(12 Dec 1998)
immunologic factors Biologically active substances whose activities affect or play a role in the functioning of the immune system.
(12 Dec 1998)
immunologic memory <immunology> The ability to rapidly produce large quantities of specific immune cells after subsequent exposure to a previously encountered antigen.
(09 Oct 1997)
immunologic pregnancy test A general term for test's for detection of increased human chorionic gonadotropin in plasma or urine by immunologic techniques including latex particle agglutination, haemagglutination inhibition, radioimmunoassay, and radioreceptor assays.
(05 Mar 2000)
immunologic surveillance The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells.
(12 Dec 1998)
immunologic tests Diagnostic techniques involving the demonstration or measurement of an immune response, including antibody production or assay, antigen-antibody reactions, serologic cross-reactivity, delayed hypersensitivity reactions, or heterogenetic responses.
(12 Dec 1998)
acoustic tolerance The maximum sound pressure level that can be experienced without producing pain or permanent defect of hearing in a normal individual.
(05 Mar 2000)
bile acid tolerance test A sensitive test of hepatic dysfunction; following oral administration of labelled or unlabelled bile acid, the measured fractional disappearance rate or 10-minute retention is measured.
(05 Mar 2000)
galactose tolerance test A liver function test, based on the ability of the liver to convert galactose to glycogen, measured by the rate of excretion of galactose following ingestion or intravenous injection of a known amount; normally, less than 3 g appear in the urine within 5 hours after the ingestion of 40 g.
(05 Mar 2000)
radiation tolerance The ability of some cells or tissues to withstand ionizing radiation without serious injury. Tolerance depends on the species, cell type, and physical and chemical variables, including radiation-protective agents and radiation-sensitizing agents.
(12 Dec 1998)
pain tolerance The greatest intensity of painful stimulation that an individual is able to tolerate.
(05 Mar 2000)
gamma-tolerance The tolerance of a person or a piece of equipment to forces that develop as a result of acceleration or deceleration.
(05 Mar 2000)
vibration tolerance The maximum vibratory or oscillatory movements that an individual can experience and bear without pain; the limit of tolerance is a function of amplitude and frequency of the vibration and varies with the direction of application.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-toned
    °¡¶ôÀÌ ³ôÀº
  • High Dutch
    =High German
  • High Street
    Å«(¹øÈ­ÇÑ) °Å¸®
  • Lord High Chancellor
    ´ë¹ý°ü
  • Middle High German
    Áß¼¼(Áß±â) °íÁö µ¶ÀϾî(12-15¼¼±â)
  • Old High German
    =GERMAN
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • extremely high frequency
    (Åë½Å)ÃʰíÁÖÆÄ
  • high
    ³ôÀº;...ÀÇ ³ôÀÌÀÇ;³ôÀº °÷(À¸·ÎºÎÅÍ)ÀÇ;°íÁöÀÇ;°í±Í(°í»ó,¼þ°í)ÇÑ;°í¿øÀÇ;°íÀ§ÀÇ;°í±ÞÀÇ;°ªºñ½Ñ;°Ý·ÄÇÑ;±ØµµÀÇ;°ú°ÝÇÑ;£Àº
  • high
    (¿¬°áÇü)(~³ôÀÌÀÇ)ÀÇ ¶æ
  • high Church
    °í±³È¸ÆÄ(¿µ±¹ ±³È¸ÆÄ Áß,±³È¸ÀÇ ±³ÀÇ ¹× ÀǽÄÀ» Á¸ÁßÇÏ´Â ÇÑÆÄ)
  • high Churchman
    °í±³È¸ÆÄ ½Åµµ
  • high Court
    °íµî¹ý¿ø
  • high German
    GERMAN
  • high Mass
    (Ä«Å縯) Àå¾öÇÑ ¹Ì»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á